NICE Guidelines Set to Reduce Unnecessary Colonoscopies

By Staff Writer

September 21, 2023

A New Era for Colorectal Cancer Diagnosis

The National Institute for Health and Care Excellence (NICE) has released new guidance that could spare tens of thousands of people the need for a colonoscopy each year. The updated guidelines recommend offering people with signs or symptoms of colorectal cancer a home test using quantitative faecal immunochemical tests (FIT).

These tests, which measure the amount of blood in the faeces, could lead to faster diagnoses and fewer referrals to secondary care for unnecessary colonoscopies. This shift in approach would allow colonoscopy services to focus on the patients who need them most, improving both patient care and healthcare efficiency.

Positive Impact on the NHS and Patient Care

The North Tees and Hartlepool NHS Foundation Trust has already implemented the approach recommended by NICE. They found that they detected more cancers using fewer colonoscopies, which is beneficial for both patients and the NHS.

Mark Chapman, interim director of medical technology and digital evaluation at NICE, said the new recommendations could help around 100,000 people avoid unnecessary colonoscopies. Furthermore, it will free up waiting lists to diagnose those more likely to have colorectal cancer.

Genevieve Edwards, chief executive at Bowel Cancer UK, added that the new guidance would help GPs identify and refer the right patients for further testing quickly, potentially detecting bowel cancer at an earlier stage when it is more treatable and curable.

With colorectal cancer being the fourth most common cancer in the UK, these new guidelines represent a significant step forward in managing its diagnosis and treatment.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.